Recruiting PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT05789082

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRAScendo 170)

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Sponsor: Hoffmann-La Roche

Conditions Non-Small Cell Lung Cancer

Interventions Carboplatin Cisplatin Divarasib Pembrolizumab Pemetrexed

Updated 31 times since 2023 Last updated: Feb 19, 2026 Started: Jun 20, 2023 Primary completion: Jan 29, 2032 Completion: Jan 29, 2032

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Non-Small Cell Lung Cancer and is currently actively recruiting participants. Hoffmann-La Roche leads this study, which shows 31 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

31 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE1/PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 26 earlier versions

Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE1/PHASE2
May 2025 — Jun 2025 [monthly]

Recruiting PHASE1/PHASE2
Apr 2025 — May 2025 [monthly]

Recruiting PHASE1/PHASE2
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE1/PHASE2
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE1/PHASE2
Dec 2024 — Feb 2025 [monthly]

Recruiting PHASE1/PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
May 2024 — Jun 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1_PHASE2
Jan 2024 — Mar 2024 [monthly]

Recruiting PHASE1_PHASE2
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1_PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1_PHASE2
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE1_PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE1_PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Badalona, Spain , Barcelona, Spain , Barretos, Brazil , Basel, Switzerland , Bern, Switzerland , Blacksburg, United States , Brussels, Belgium , Buenos Aires, Argentina , Busan, South Korea and 54 more locations